Home | Welcome to Contract Pharma   
Last Updated Saturday, May 25 2013
Print RSS Feed

Breaking News


April 8, 2013
Assists early research efforts in tumor targets  Read More »

April 5, 2013
Will evaluate regulatory, commercial circumstances before further investment  Read More »

April 5, 2013
Will operate under the name Ajinomoto Althea  Read More »

April 5, 2013
Will promote five products in the U.S.  Read More »

April 5, 2013
Will use conjugation technology to develop ADCs in oncology  Read More »

April 5, 2013
Will evaluate VX-135 and daclatasvir in hepatitis C  Read More »

April 4, 2013
Cytoskeletal offerings aim to shorten development times  Read More »

April 4, 2013
Will evaluate Durasert and Tethadur technologies for ophthalmics  Read More »

April 4, 2013
Portsmouth UK center will include large scientific area  Read More »

April 4, 2013
To develop novel antibody program from X-BODY platform  Read More »

April 4, 2013
To develop CHO cell lines and assess product attributes for proteins  Read More »

April 3, 2013
Gains broader DEA license for pain therapeutics and controlled-substances  Read More »

April 3, 2013
Becomes the largest pharma samples management provider in the U.S.  Read More »

April 3, 2013
Adds early-stage cardiovascular drug  Read More »

April 3, 2013
Gains access to Captisol technology  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On